Hexigone Inhibitors Secures £174k in Latest Funding Round

Hexigone Inhibitors Limited, a company specialising in smart, sustainable anti-corrosive additives for coatings, has successfully raised £174k in its latest funding round. The Port Talbot-based firm, which lists its headquarters in Swansea on its LinkedIn profile, achieved an estimated post-money valuation of £3.9m with this recent capital injection.

Incorporated on 10 June 2016, Hexigone Inhibitors addresses a critical need in various industrial sectors by developing advanced anti-corrosion solutions. The company manufactures highly effective additives for coatings, utilising its proprietary Intelli-ion® technology. This innovative approach aims to replace traditional, often toxic, corrosion inhibitors with more environmentally friendly and high-performance alternatives. Their products are adopted by coating manufacturers across diverse industries, including marine, aerospace, automotive, industrial, and construction, to enhance the protection of metal assets.

The core of Hexigone Inhibitors' offering is Intelli-ion®, an ion-exchange corrosion inhibitor developed by materials scientists. This technology is designed to activate "on-demand," thereby extending asset protection and assisting coatings manufacturers in meeting increasingly stringent performance and regulatory requirements. A key benefit highlighted by the company is the ultra-low loading levels required for Intelli-ion®, which reduces the overall amount of inhibitor needed. This not only delivers significant cost savings for manufacturers but also maintains high performance standards. The versatility of Intelli-ion® allows it to be formulated into all coatings chemistries and post-added to solvent-based coatings.

The recent funding round, with an estimated size of £174k, was filed on 21 April 2026, following an allotment date of 1 February 2026. This round places the company's post-money valuation at £3.9m. This marks another step in Hexigone Inhibitors' funding journey, which has seen several rounds of investment since its inception.

A review of the company's funding history reveals a dynamic valuation trajectory. Prior to this latest round, Hexigone Inhibitors secured £154.1k on 14 January 2025, at an estimated valuation of £6.2m. This indicates a decrease in valuation in the most recent round compared to early 2025. In 2024, the company completed two funding rounds on the same date, 22 February. One round raised £250k at a valuation of £3.1m, while another brought in £807.8k at a valuation of £4m. Further back, on 19 May 2023, Hexigone Inhibitors raised £293.9k at a valuation of £3.9m, aligning with the current round's valuation. Earlier rounds include £1.1m raised on 10 June 2022, at a £3.6m valuation, and £294.8k on 16 February 2021, at a £2.6m valuation.

According to its latest available accounts and LinkedIn profile, Hexigone Inhibitors currently employs 9 individuals, reflecting a focused team dedicated to advancing its chemical manufacturing innovations.

In the broader UK funding landscape, companies like Hexigone Inhibitors, operating in the chemical manufacturing and materials science sectors, play a crucial role in driving innovation towards more sustainable industrial practices. The emphasis on replacing toxic inhibitors with high-performance, eco-friendly alternatives positions the company well within a global push for green technologies and reduced environmental impact in manufacturing. While specific sector-wide funding data for "Manufacture of other chemical products" is not detailed here, the continued investment in Hexigone Inhibitors underscores the perceived value of its DeepTech solutions in addressing critical industry challenges related to corrosion protection and sustainability. The company's ability to attract consistent, albeit fluctuating, investment highlights the ongoing demand for advanced materials that offer both performance and environmental responsibility.